New drug combo tested for young adults with untreated leukemia
NCT ID NCT02158091
Summary
This study is testing a new drug called IPI-145 in combination with a standard chemotherapy regimen (FCR) for younger adults who have never been treated for chronic lymphocytic leukemia (CLL). The first part aims to find the safest dose, and the second part aims to see how well the combination works to achieve a deep remission with no detectable cancer cells. It involves about 32 participants aged 18-65.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Isreal Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.